Raphael Rousseau, Chief Medical Officer
Professional Overview
Raphael Rousseau is an accomplished physician-scientist with extensive expertise in drug development and biotechnology. As the Chief Medical Officer at Pheast Therapeutics, he oversees the company's clinical strategy and leads the medical affairs team in advancing innovative therapies to improve patient outcomes.
Experience Summary
Current Role
As Chief Medical Officer at Pheast Therapeutics since 2025, Raphael is responsible for providing strategic direction and medical leadership to the organization. He works closely with the research and development teams to design and execute clinical trials, ensure compliance with regulatory requirements, and manage the safety and efficacy profiles of the company's drug candidates. Under his guidance, Pheast has successfully navigated the clinical development process and secured multiple regulatory approvals for its novel treatments.
Career Progression
Prior to his current role, Raphael served as a freelance consultant for drug development at Kerisper Biopharma Consulting, where he advised biotechnology and pharmaceutical companies on clinical trial design, regulatory affairs, and market access strategies. He has also held positions as a member of the Board of Directors at Oncoheroes Biosciences and as a scientific advisor for JEITO and Owkin, leveraging his deep understanding of the industry to provide strategic insights and guide the development of transformative therapies.
Academic Background
Raphael holds a medical degree and has completed specialized training in internal medicine and oncology. His academic credentials and research contributions have established him as a respected thought leader in the field of drug development.
Areas of Expertise
- Clinical trial design and execution
- Regulatory affairs and compliance
- Medical affairs and safety monitoring
- Translational research and biomarker development
- Strategic decision-making and leadership
Professional Impact
Raphael's expertise and contributions have had a significant impact on the advancement of new therapies in the biotechnology industry. He has played a pivotal role in the successful development and commercialization of several groundbreaking treatments, helping to improve patient outcomes and transform the lives of those affected by complex medical conditions.
Conclusion
With his extensive experience, deep scientific knowledge, and proven track record of success, Raphael Rousseau is a highly respected and sought-after leader in the biotechnology industry. As the Chief Medical Officer at Pheast Therapeutics, he continues to drive innovation and deliver on the company's mission to develop transformative therapies that address unmet medical needs.
